MX348464B - Agente inductor de inmunidad. - Google Patents

Agente inductor de inmunidad.

Info

Publication number
MX348464B
MX348464B MX2015000895A MX2015000895A MX348464B MX 348464 B MX348464 B MX 348464B MX 2015000895 A MX2015000895 A MX 2015000895A MX 2015000895 A MX2015000895 A MX 2015000895A MX 348464 B MX348464 B MX 348464B
Authority
MX
Mexico
Prior art keywords
polypeptide
agent
immunity
seq
immunity inducing
Prior art date
Application number
MX2015000895A
Other languages
English (en)
Spanish (es)
Inventor
Okano Fumiyoshi
Saito Takanori
Shimizu Masaki
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX348464B publication Critical patent/MX348464B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2015000895A 2008-08-05 2009-08-05 Agente inductor de inmunidad. MX348464B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008202065 2008-08-05
PCT/JP2009/063881 WO2010016525A1 (ja) 2008-08-05 2009-08-05 免疫誘導剤

Publications (1)

Publication Number Publication Date
MX348464B true MX348464B (es) 2017-06-14

Family

ID=41663742

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2011001113A MX339277B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.
MX2015000895A MX348464B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2011001113A MX339277B (es) 2008-08-05 2009-08-05 Agente inductor de inmunidad.

Country Status (16)

Country Link
US (2) US8454968B2 (OSRAM)
EP (2) EP2837383B1 (OSRAM)
JP (2) JP5691171B2 (OSRAM)
KR (3) KR102009241B1 (OSRAM)
CN (2) CN103751771B (OSRAM)
AU (2) AU2009278385B2 (OSRAM)
BR (2) BRPI0912462B1 (OSRAM)
CA (1) CA2732283C (OSRAM)
DK (2) DK2837383T3 (OSRAM)
ES (2) ES2539603T3 (OSRAM)
HU (1) HUE031343T2 (OSRAM)
MX (2) MX339277B (OSRAM)
PL (2) PL2324842T3 (OSRAM)
PT (2) PT2324842E (OSRAM)
RU (2) RU2511039C2 (OSRAM)
WO (1) WO2010016525A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101667319B1 (ko) 2008-08-05 2016-10-18 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
ES2570731T3 (es) * 2008-08-05 2016-05-20 Toray Industries Método de detección de cáncer
CA2788720C (en) * 2010-02-04 2019-08-20 Takayoshi Ido Medicament for treating and/or preventing cancer
WO2011096533A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
KR101758117B1 (ko) 2010-02-04 2017-07-14 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CN102821788B (zh) 2010-02-04 2016-11-16 东丽株式会社 癌的治疗和/或预防用药物组合物
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2011096517A1 (ja) * 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2711017B1 (en) * 2011-05-19 2016-08-03 Toray Industries, Inc. Immunity inducing agent
DK2740794T3 (en) 2011-08-04 2018-06-14 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR CANCER PREVENTION
EP2740798B1 (en) * 2011-08-04 2016-12-07 Toray Industries, Inc. Cancer treatment and/or prevention drug composition
HUE035689T2 (en) * 2011-08-04 2018-05-28 Toray Industries A pharmaceutical composition for the treatment and / or prevention of cancer
ES2634249T3 (es) 2011-08-04 2017-09-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la profilaxis del cáncer
PT2740795T (pt) 2011-08-04 2017-01-09 Toray Industries Composição de fármaco para o tratamento e/ou a prevenção de cancro
CA2844037C (en) 2011-08-04 2020-07-14 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
HUE033628T2 (en) * 2011-08-04 2017-12-28 Toray Industries Method for detecting pancreatic cancer
PL2818483T3 (pl) 2012-02-21 2018-01-31 Toray Industries Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi
RU2633505C2 (ru) 2012-02-21 2017-10-12 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR102009238B1 (ko) 2012-02-21 2019-08-09 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
RU2639522C2 (ru) 2012-02-21 2017-12-21 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
DK2832366T3 (en) * 2012-03-30 2018-01-22 Toray Industries PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF Gallbladder cancer
CN104220095B (zh) * 2012-03-30 2016-09-07 东丽株式会社 肝癌的治疗和/或预防用药物组合物
CN104471403B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
PT2876447T (pt) 2012-07-19 2020-02-03 Toray Industries Método para deteção de cancro
ES2704909T3 (es) 2013-08-09 2019-03-20 Toray Industries Composición farmacéutica para el tratamiento y/o la prevención del cáncer
CN107530411B (zh) * 2015-04-30 2021-08-13 东丽株式会社 免疫诱导剂
US12274745B2 (en) * 2016-10-28 2025-04-15 Toray Industries, Inc. Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment
CA3095719A1 (en) * 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
CN109206502B (zh) * 2018-09-26 2022-03-04 东北农业大学 一种猫干扰素ω及其制备方法和在抗病毒中的应用
CN109206501B (zh) * 2018-09-26 2022-03-04 东北农业大学 猫干扰素ω、其编码基因及其在抗病毒方面的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
KR20010083111A (ko) * 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
WO2002083070A2 (en) * 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
US20030190640A1 (en) * 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US8211634B2 (en) 2006-02-14 2012-07-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
KR20080075722A (ko) 2007-02-13 2008-08-19 엘지이노텍 주식회사 튜너
JP4826496B2 (ja) 2007-02-16 2011-11-30 三菱マテリアル株式会社 電解メッキ用アノード電極取付構造
WO2013143026A1 (en) * 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
WO2014197471A1 (en) * 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma

Also Published As

Publication number Publication date
KR102009241B1 (ko) 2019-08-09
PL2324842T3 (pl) 2015-08-31
PL2837383T3 (pl) 2017-07-31
EP2837383B1 (en) 2016-12-14
BR122020027042B1 (pt) 2022-11-08
EP2837383A1 (en) 2015-02-18
JP5691171B2 (ja) 2015-04-01
BRPI0912462A2 (OSRAM) 2016-02-02
CN103751771A (zh) 2014-04-30
US9592281B2 (en) 2017-03-14
AU2015210461A1 (en) 2015-09-03
CA2732283A1 (en) 2010-02-11
CN103751771B (zh) 2017-09-08
CA2732283C (en) 2017-12-05
WO2010016525A1 (ja) 2010-02-11
KR101669827B1 (ko) 2016-10-27
MX2011001113A (es) 2011-03-04
EP2324842A4 (en) 2012-05-23
PT2324842E (pt) 2015-07-21
DK2837383T3 (en) 2017-03-20
JP2015061847A (ja) 2015-04-02
US20130230488A1 (en) 2013-09-05
ES2539603T3 (es) 2015-07-02
JP5962739B2 (ja) 2016-08-03
KR20160127146A (ko) 2016-11-02
KR20110044854A (ko) 2011-05-02
RU2511039C2 (ru) 2014-04-10
PT2837383T (pt) 2017-03-17
AU2009278385B2 (en) 2015-06-11
RU2011108315A (ru) 2012-09-10
HUE031343T2 (hu) 2017-07-28
EP2324842A1 (en) 2011-05-25
EP2324842B1 (en) 2015-03-25
AU2009278385A1 (en) 2010-02-11
CN102112146A (zh) 2011-06-29
BRPI0912462B1 (pt) 2022-03-22
JPWO2010016525A1 (ja) 2012-01-26
CN102112146B (zh) 2014-03-12
DK2324842T3 (da) 2015-06-22
US20110123492A1 (en) 2011-05-26
US8454968B2 (en) 2013-06-04
ES2619322T3 (es) 2017-06-26
AU2015210461B2 (en) 2017-07-13
RU2013156620A (ru) 2015-06-27
RU2639518C2 (ru) 2017-12-21
MX339277B (es) 2016-05-19
KR20170128637A (ko) 2017-11-22

Similar Documents

Publication Publication Date Title
MX348464B (es) Agente inductor de inmunidad.
ES2565060T3 (es) Polipéptidos que tienen actividad de glucoamilasa y polinucleótidos que codifican los mismos
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
MX2009004147A (es) Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1.
EA201500802A1 (ru) Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы
CO7240398A2 (es) Polipéptidos que tienen actividad de transgalactosilación
MX2024015050A (es) L-asparaginasa modificada
AR080658A1 (es) Toxinas insecticidas cry dig-5 de bacillus thuringiensis
GT201700224A (es) Proteína de unión a rgma y su uso
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
CR20150196A (es) Moléculas de unión il-17a novedosas y usos médicos de las mismas
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
MX2021009696A (es) Vectores de genoterapia para el tratamiento de la enfermedad de danon.
PE20220960A1 (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidopteros
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
MX344183B (es) Proteina antimicrobiana.
MX392412B (es) Polipéptidos que tienen actividad inductora de inmunidad.
ES2536238T3 (es) Péptidos antimicrobianos
CO6362049A2 (es) Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo
MY171183A (en) Polypeptide glycosylated with sialylated sugar chain
BR112013002702A2 (pt) vacina
WO2013088371A3 (en) Use of the mmp-12 protein in the prevention and/or treatment of dandruff conditions of the scalp
GB201018125D0 (en) Peptide
BR112013029596B8 (pt) Composição imunogênica